

Prescription & Enrollment Form Enspryng® (satralizumab-mwge)

Four simple steps to submit your referral.

1 PATIENT INFORMATION

New patient Current patient

Patient's first name _____
 Last name _____ Middle initial _____
 Date of birth _____ Male Female Last 4 digits of SSN _____
 Street address _____ Apt # _____
 City _____ State _____ Zip _____
 Parent/guardian (if applicable) _____
 Home phone _____
 Cell phone _____
 Work phone _____
 E-mail address _____
 Patient's primary language: English Other
 If other, please specify _____

Please attach copies of front and back of patient's insurance cards or complete information below.

Insurance company _____
 Phone _____
 Insured's name _____
 Insured's employer _____
 Relationship to patient _____
 Identification # _____
 Policy/group # _____
 Prescription card: Yes No
 If yes, carrier _____
 Policy # _____
 Group # _____
 Is patient eligible for Medicare? Yes No
 Does patient have a secondary insurance? Yes No

2 PRESCRIBER INFORMATION

All fields must be completed to expedite prescription fulfillment.

Date _____ Time _____ Date medication needed _____
 Prescriber's first name _____
 Last name _____
 Prescriber's title _____
 If NP or PA, under direction of Dr. _____
 Office contact and title _____
 Office contact e-mail _____
 Office/clinic/institution name _____
 Clinic/hospital affiliation _____
 Street address _____ Suite # _____
 City _____ State _____ Zip _____
 Phone _____
 Fax _____
 NPI # _____ License # _____
 Deliver product to patient's home.

3 CLINICAL INFORMATION

Primary ICD-10 code: _____
Diagnosis
 G36.0 Neuromyelitis optica Other _____
 Is the patient anti-aquaporin-4 antibody positive? Yes No Test pending
 Prior NSMOD therapies tried/failed _____
 Hep B vaccination: Yes No Date _____
 Does the patient have active Hepatitis B infection? Yes No
 Hepatitis B screening:
 Hepatitis B surface antigen (HBsAg) results Positive Negative Date _____
 HB core antibody [HBcAb+] results Positive Negative Date _____
 Does the patient have active or latent TB infection? Yes No
 Tuberculosis screening: Positive Negative Date _____
 NKDA Known drug allergies _____
 Concurrent meds _____

4 PRESCRIBING INFORMATION

Medication	Strength/Formulation	Directions	Quantity/Refills
Enspryng® (satralizumab-mwge)	120 mg/mL prefilled syringe	<input type="checkbox"/> Treatment naïve: Inject 120 mg subcutaneously at weeks 0, 2 and 4, followed by 120 mg every 4 weeks. <input type="checkbox"/> Restart (if 8 to <12 weeks since last dose) Inject 120 mg subcutaneously upon restarting and at 2 weeks, followed by 120 mg every 4 weeks. <input type="checkbox"/> Restart (if ≥12 weeks since last dose) Inject 120 mg subcutaneously at weeks 0, 2 and 4, followed by 120 mg every 4 weeks.	1-month supply Refills _____

By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. **NO STAMPS**)

PHYSICIAN SIGNATURE REQUIRED

Date _____ Dispense as written _____ Date _____ Substitution allowed _____

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, substitution prevention, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Please fax completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.412.4764.

You can now monitor shipments and chat online if you have questions.

Go to MyAccredoPatients.com to log in or get started.